Patents by Inventor Mingyan XU

Mingyan XU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11931389
    Abstract: The present invention provides a tablet of sporoderm-removed Ganoderma lucidum spore, which includes the following raw materials by weight parts: 13-20 parts of an aqueous extract of sporoderm-disrupted Ganoderma lucidum spore powder, 3-5 parts of sorbitol, and 0.8-1.2 parts of povidone K30; A method for preparing the tablet of sporoderm-removed Ganoderma lucidum spore includes the following steps: mixing the aqueous extract of sporoderm-disrupted Ganoderma lucidum spore powder, sorbitol and povidone K30 for 10-30 min, and subjecting the obtained mixture to granulating, screening and drying to obtain a granular material; and tableting the granular material to obtain the tablet of sporoderm-removed Ganoderma lucidum spore. The tablet of sporoderm-removed Ganoderma lucidum spore has a much higher content of active components, which are also easier to be absorbed.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 19, 2024
    Assignees: Zhejiang Shouxiangu Pharmaceutical Company, Ltd., Jinhua Shouxiangu Pharmaceutical Co. Ltd
    Inventors: Zhenhao Li, Mingyan Li, Ying Wang, Huaxian Zheng, Jing Xu
  • Patent number: 11674137
    Abstract: Disclosed is an adaptor for sequencing DNAs at ultratrace levels and its uses. The adaptor contains, from 5?terminus to 3?terminus, a Tag sequence, PolyNs, a first stem sequencing, a first loop sequence, dUTP(s), a second loop sequence, and a second stem sequence, wherein the second stem sequence is complementary to the first stem sequence when read in opposite directions, and the 5?terminus of the adaptor is phosphorylated. The adaptor is designed to form a hairpin structure itself in use and then ligated to a DNA molecule of interest, so that adaptor-adaptor ligation can be effectively avoided, eliminating the inefficient adaptor-DNA ligation problem. Such an adaptor is especially suitable for library construction and sequencing of DNAs at ultratrace levels, laying a good basis for accurate sequencing of ctDNAs.
    Type: Grant
    Filed: May 27, 2017
    Date of Patent: June 13, 2023
    Inventors: Xiaoni Zhang, Ming Liu, Guolin Zhong, Mingyan Xu
  • Publication number: 20220281904
    Abstract: A prodrug platform is useful to deliver pharmaceutically active amines, amides and phenols and their use in the diagnosis, prevention and/or treatment of various diseases. Compared with the parent drug (e.g., Gemcitabine), the prodrugs show a significant overall safety improvement (therapeutic index (TI) improvement), especially in liver. The prodrugs can treat several diseases, including, for example, cancer, metabolic disease, viral infection, immunological disease, neurologic disease, and blood disease.
    Type: Application
    Filed: August 18, 2020
    Publication date: September 8, 2022
    Inventor: Mingyan XU
  • Publication number: 20200063125
    Abstract: Disclosed is an adaptor for sequencing DNAs at ultratrace levels and its uses. The adaptor contains, from 5?terminus to 3?terminus, a Tag sequence, PolyNs, a first stem sequencing, a first loop sequence, dUTP(s), a second loop sequence, and a second stem sequence, wherein the second stem sequence is complementary to the first stem sequence when read in opposite directions, and the 5?terminus of the adaptor is phosphorylated. The adaptor is designed to form a hairpin structure itself in use and then ligated to a DNA molecule of interest, so that adaptor-adaptor ligation can be effectively avoided, eliminating the inefficient adaptor-DNA ligation problem. Such an adaptor is especially suitable for library construction and sequencing of DNAs at ultratrace levels, laying a good basis for accurate sequencing of ctDNAs.
    Type: Application
    Filed: May 27, 2017
    Publication date: February 27, 2020
    Inventors: Xiaoni ZHANG, Ming LIU, Guolin ZHONG, Mingyan XU
  • Patent number: 9944993
    Abstract: The present invention provides a method and a reagent for enrichment of circulating tumor DNA, the method comprising the steps of mixing a water phase and an oil phase and shaking the mixture to prepare an emulsion PCR reaction system, and performing emulsion PCR amplification, wherein the water phase comprises peripheral blood plasma DNA as template DNA, a forward primer and a reverse primer, dNTPs, a PCR buffer and a DNA polymerase, the peripheral blood plasma DNA having adapter sequences connected to both ends thereof, and the forward primer and the reverse primer being complementary to the adapter sequences at the two ends respectively; separating the water phase from the oil phase following the emulsion PCR amplification to obtain a PCR amplification product in the water phase; and capturing circulating tumor DNA in the PCR amplification product in the water phase by using a probe sequence that specifically binds to the circulating tumor DNA.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: April 17, 2018
    Assignee: Haplox Biotechnology (Shenzhen) Co., Ltd.
    Inventors: Mingyan Xu, Xiaoni Zhang
  • Publication number: 20170067117
    Abstract: The present invention provides a method and a reagent for enrichment of circulating tumor DNA, the method comprising the steps of mixing a water phase and an oil phase and shaking the mixture to prepare an emulsion PCR reaction system, and performing emulsion PCR amplification, wherein the water phase comprises peripheral blood plasma DNA as template DNA, a forward primer and a reverse primer, dNTPs, a PCR buffer and a DNA polymerase, the peripheral blood plasma DNA having adapter sequences connected to both ends thereof, and the forward primer and the reverse primer being complementary to the adapter sequences at the two ends respectively; separating the water phase from the oil phase following the emulsion PCR amplification to obtain a PCR amplification product in the water phase; and capturing circulating tumor DNA in the PCR amplification product in the water phase by using a probe sequence that specifically binds to the circulating tumor DNA.
    Type: Application
    Filed: January 6, 2015
    Publication date: March 9, 2017
    Inventors: Mingyan XU, Xiaoni ZHANG